*Or you can buy the full cannabis/hemp stocks directory in PDF format for $24.95 Buy Now
Directories are not refundable
1933 Industries Inc. (CSE:TGIF.C; OTCQB:TGIFF) Based in Las Vegas, Nevada, Friday Night Inc. is focused on the production and sales of medical marijuana and innovative cannabis products. The State of Nevada currently regulates and controls medical marijuana, and has announced its intention to do the same for recreational use as early as July, 2017.
22nd Century Group Inc. (NYSE MKT:XXII) is a plant biotechnology company focused on technology which allows it to increase or decrease the level of nicotine in tobacco plants and the level of cannabinoids in cannabis plants through genetic engineering and plant breeding. The Company's primary mission is to reduce the harm caused by smoking. 22nd Century currently owns or exclusively controls more than 200 issued patents and more than 50 pending patent applications around the world. The Company's strong IP position led to a licensing agreement with British American Tobacco ("BAT"), the world's second largest tobacco company.
3DX Industries Inc. (OTC: DDDX) is focused on the additive metal manufacturing segment within the manufacturing industry. 3DX has the capability of manufacturing a wide variety of products using its 3D metal printing system, 3D composite printing as well as more traditional methods of precision manufacturing. 3DX offers additive and subtractive manufacturing options as well as product design, engineering and assembly services to its customers. Cannabis: Has completed the development and design of a new and innovative product used for recovering excess heat from high energy grow lights. The part was designed specifically for the legalized cannabis markets including medical marijuana using the company's 3D Metal printing -- Binder Additive manufacturing process and is expected to be installed in select licensed facilities for real world testing in the coming months.
48North Cannabis Corp. (TSX:NRTH.V) is a TSXV Venture Exchange listed company whose wholly owned subsidiary DelShen Therapeutics Corp. ("DelShen"), is a licensed producer of medical cannabis in Canada. 48North grows unique genetics sourced from MariPharm B.V., a Netherlands-based phytopharmaceutical company with over 25 years of experience in the research and cultivation of cannabis for medical purposes. Its genetics are grown to exacting standards, ensuring patients can count on receiving the highest-quality cannabis products. DelShen is regulated by the Access to Cannabis for Medical Purposes Regulations ("ACMPR") and the facility is located on 800-acres of owned land near Kirkland Lake, Ontario. DelShen's license to produce cannabis was granted on Feb. 28, 2017, and pertains to the facility, a state-of-the-art, closed-box, 40,000-square-foot building with an additional
ABATTIS BIOCEUTICALS (OTC:ATTBF; CSE:ATT) is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its mass cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions.
ABcann Global Corporation (TSX:ABCN.V) was one of the first companies to obtain a production license under the Marijuana for Medical Purposes Regulations, which it received on March 21, 2014. It obtained a sales license on December 31, 2015. ABcann's flagship facility, in Napanee, Ontario, contains proprietary plant-growing technology, including environmentally-controlled chambers capable of monitoring and regulating all variables in the growing process. This approach and the systems in place allow ABcann to produce organically grown and pesticide-free, high-yielding plants, which, in turn, can generate high-quality products that are consistent from batch to batch. ABcann is able to control environmental and nutrient demands, tailor-made for a particular strain of cannabis, without the variation that is typical when producing large quantities in less-controlled, larger rooms and greenhouse-type structures. ABcann's modular approach to systems technology eliminates scale-up risk and allows ABcann to locate anywhere in the world and maintain consistency and quality of product. ABcann is expanding capacity in its current facility to approximately 30,000 sq ft and concurrently undertaking expansion into a new 150,000 sq ft facility in Napanee. ABcann is pursuing opportunities in Germany, Australia and other jurisdictions as well as exploring the development of multiple delivery vehicles.
Acology Inc (OTC:ACOL) markets and sells the TSOS Container™ (The Science of Storage).This container is the first-ever FDA approved polypropylene air-tight, water-tight, smell-proof delivery and storage container with a built-in grinder. It is manufactured from medical-grade No. 5 polypropylene resin, which is non-porous and non-leaching. These containers are portable and affordable. he Medtainer™ allows patients to store, grind and pour a variety of medications, including pills and all sizes and solidity, herbal medications and teas and even coffee and spices! The Medtainer™ can be ordered in with a certified child-resistant cap. Each Medtainer™ is water-proof and smell proof. Caregivers who are responsible for ensuring their patients medication regimens are universally pleased with the how easy and effective the Medtainer™ grind medications. It is an excellent solution for patients with dysphasia due to cognitive disorders or brain injuries, are in hospice or palliative situations and for anyone who would rather not swallow whole pills. The MedTainer™ was originally developed for geriatric and pediatric patients who had difficulty swallowing pills or needed an effective alternative to costly name-brand medications. The MedTainer™ has been sold and is being successfully used throughout the United States, Canada, Mexico and South America and Europe. Our association with the Medical Marijuana community was an unexpected windfall that has given Acology, Inc. the necessary funding to expand into the growing hospice and palliative care markets, and to help countless patients who are living at home or in small home-like settings and need help swallowing pills.
Acreage Holdings, Inc. (CSE:ACRG.U) is a vertically integrated, multi-state owner of cannabis licenses and assets in U.S. states where either medical and/or adult use of cannabis is legal. With one of the largest geographic footprints of any cannabis company, it currently owns and/or operates cultivation, processing and dispensary operations. Acreage is dedicated to building and scaling operations to create a seamless, consumer-focused branded cannabis experience.
Advantis Corp (OTC:ADVT) develops products and works with developing companies to provide innovative healthcare products, holistic pain management solutions, and enhance the footprint in the evolving legal cannabis business. Advantis acquires ownership in developing companies that work within the nutraceutical and the alternative health care industries; consulting with these organizations to improve their product lines, expand their distribution channels through internal partnership agreements, and heighten brand value.
Aequus Pharmaceuticals Inc. (TSX:AQS.V) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus has grown its pipeline to include several commercial products in ophthalmology and transplant, and a development stage pipeline in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. As a complement to its focus in neurology, our most recent addition to the development pipeline was a long-acting form of medical cannabis, where there is a high need for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas.
Our site does not give specific recommendations and encourages investors to complete their own due diligence. Our lists are compiled from internal and external research sources. Our lists are to be used only as a partial source of due diligence.